Successful use of an immune checkpoint inhibitor in a patient with myasthenia gravis in remission

Muscle Nerve. 2019 Jul;60(1):E7-E8. doi: 10.1002/mus.26495. Epub 2019 May 7.

Authors

Berit Jordan^{1

2}, Stephan Zierz¹, Thomas Weber³, Karin Jordan^{3

4}

Affiliations

¹ Department of Neurology, University of Halle, Halle, Germany.
² Department of Neurology, University of Heidelberg, Heidelberg, Germany.
³ Department of Medicine IV, Hematology and Oncology, University of Halle, Halle, Germany.
⁴ Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany.

PMID: 31018243
DOI: 10.1002/mus.26495

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents, Immunological / therapeutic use*
Azathioprine / therapeutic use
Central Nervous System Neoplasms / complications
Central Nervous System Neoplasms / drug therapy*
Cholinesterase Inhibitors / therapeutic use
Female
Glucocorticoids / therapeutic use
Humans
Immunosuppressive Agents / therapeutic use
Lymphoma / complications
Lymphoma / drug therapy*
Maintenance Chemotherapy
Middle Aged
Myasthenia Gravis / complications*
Myasthenia Gravis / therapy
Neoplasm Recurrence, Local / complications
Neoplasm Recurrence, Local / drug therapy*
Nivolumab / therapeutic use*
Prednisone / therapeutic use
Pyridostigmine Bromide / therapeutic use
Remission Induction
Thymectomy

Substances

Antineoplastic Agents, Immunological
Cholinesterase Inhibitors
Glucocorticoids
Immunosuppressive Agents
Nivolumab
Pyridostigmine Bromide
Azathioprine
Prednisone